SCLX Key Statistics, Chart & Performance
The current stock price of SCLX is 13.26 USD. In the past month the price decreased by -31.65%. In the past year, price decreased by -16.66%.
SCLX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 47.36 | 984.62B | ||
| JNJ | JOHNSON & JOHNSON | 19.68 | 492.24B | ||
| MRK | MERCK & CO. INC. | 12.2 | 266.67B | ||
| PFE | PFIZER INC | 7.87 | 143.11B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.09 | 108.02B | ||
| ZTS | ZOETIS INC | 20.41 | 57.01B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.65 | 22.89B | ||
| VTRS | VIATRIS INC | 5.31 | 14.25B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.01 | 11.45B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.64B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.56B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 4.57B |
Related stock screener links
About SCLX
Company Profile
Scilex Holding Co. engages in the acquisition, development, and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. The company is headquartered in Palo Alto, California and currently employs 30 full-time employees. The company went IPO on 2021-01-11. The Company’s commercial products include ZTlidoO (lidocaine topical system) 1.8% for the relief of neuropathic pain associated with postherpetic neuralgia (PHN); ELYXYB, a ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. In addition, it focuses on product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXAO), an epidural injections formulation to treat lumbosacral radicular pain, or sciatica; SP-103 (lidocaine topical system) 5.4%, a ZTlido formulation, for the treatment of acute pain; and SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (SP-104) for fibromyalgia treatment.
Company Info
SCILEX HOLDING CO
960 San Antonio Road
Palo Alto CALIFORNIA US
Employees: 30
Phone: 16505164310
SCILEX HOLDING CO / SCLX FAQ
Can you describe the business of SCILEX HOLDING CO?
Scilex Holding Co. engages in the acquisition, development, and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. The company is headquartered in Palo Alto, California and currently employs 30 full-time employees. The company went IPO on 2021-01-11. The Company’s commercial products include ZTlidoO (lidocaine topical system) 1.8% for the relief of neuropathic pain associated with postherpetic neuralgia (PHN); ELYXYB, a ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. In addition, it focuses on product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXAO), an epidural injections formulation to treat lumbosacral radicular pain, or sciatica; SP-103 (lidocaine topical system) 5.4%, a ZTlido formulation, for the treatment of acute pain; and SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (SP-104) for fibromyalgia treatment.
Can you provide the latest stock price for SCILEX HOLDING CO?
The current stock price of SCLX is 13.26 USD. The price increased by 1.3% in the last trading session.
What is the dividend status of SCILEX HOLDING CO?
SCLX does not pay a dividend.
What is the ChartMill rating of SCILEX HOLDING CO stock?
SCLX has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Which stock exchange lists SCLX stock?
SCLX stock is listed on the Nasdaq exchange.
What do analysts say about SCILEX HOLDING CO (SCLX) stock?
6 analysts have analysed SCLX and the average price target is 499.8 USD. This implies a price increase of 3669.23% is expected in the next year compared to the current price of 13.26.
Can you provide the short interest for SCLX stock?
The outstanding short interest for SCILEX HOLDING CO (SCLX) is 2.2% of its float.
SCLX Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to SCLX. When comparing the yearly performance of all stocks, SCLX is a bad performer in the overall market: 82.37% of all stocks are doing better.
SCLX Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
SCLX Forecast & Estimates
6 analysts have analysed SCLX and the average price target is 499.8 USD. This implies a price increase of 3669.23% is expected in the next year compared to the current price of 13.26.